Lymecycline reverses acquired EGFR-TKI resistance in non–small-cell lung cancer by targeting GRB2

Chen Yang(Wenzhou Medical University), Xuejun Hu(Zoucheng People's Hospital), Hongfei Yan(First Hospital of China Medical University), Jie Wu(Shanghai Jiao Tong University), Xiaofang Che(First Hospital of China Medical University), Dan Zou(Mianyang Central Hospital), Ye Zhang(University of Electronic Science and Technology of China), Yizhe Wang(First Hospital of China Medical University), Yi Yang(China Medical University), Cheng Yang(Northeast Electric Power University), Kezuo Hou(First Hospital of China Medical University), Xiujuan Qu(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Mingming Deng(China West Normal University)
Pharmacological Research
June 16, 2020
10.1016/j.phrs.2020.105007
Cited by 34

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417